127 related articles for article (PubMed ID: 38705565)
1. Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner.
Song Y; Lian S; Fan H; Ma C; Zheng L; Huang F; Huang S; Tang Y; Shi A; Shu L; Zhao L; Xu Y; Guo S; Liu Z; Zhang Z
Cancer Lett; 2024 Jun; 592():216921. PubMed ID: 38705565
[TBL] [Abstract][Full Text] [Related]
2. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner.
Liu Z; Hu C; Zheng L; Liu J; Li K; Li X; Wang Y; Mu W; Chen T; Shi A; Qiu B; Zhang X; Zhang Z; Xu Y
Cell Mol Life Sci; 2022 Aug; 79(9):469. PubMed ID: 35932322
[TBL] [Abstract][Full Text] [Related]
3. The deubiquitinase USP5 promotes cholangiocarcinoma progression by stabilizing YBX1.
Ning F; Du L; Li J; Wu T; Zhou J; Chen Z; Hu X; Zhang Y; Luan X; Xin H; Yuan C; Zhang X
Life Sci; 2024 Jul; 348():122674. PubMed ID: 38692507
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
Liu B; Hu Y; Qin L; Peng XB; Huang YX
Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
[TBL] [Abstract][Full Text] [Related]
5. FUT4 promotes the progression of Cholangiocarcinoma by modulating epithelial-mesenchymal transition.
Liu E; Qian X; He Y; Chen K
Cell Cycle; 2024 Jan; 23(2):218-231. PubMed ID: 38466946
[TBL] [Abstract][Full Text] [Related]
6. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
7. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
[TBL] [Abstract][Full Text] [Related]
8. SP1-induced HOXD-AS1 promotes malignant progression of cholangiocarcinoma by regulating miR-520c-3p/MYCN.
Li J; Jiang X; Li Z; Huang L; Ji D; Yu L; Zhou Y; Cui Y
Aging (Albany NY); 2020 Aug; 12(16):16304-16325. PubMed ID: 32857725
[TBL] [Abstract][Full Text] [Related]
9. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract][Full Text] [Related]
10. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
Zhang C; Wang Y; Wu G; Sun N; Bai H; Li X; Han S; Zhou H; Qi R; Zhang J
Biol Direct; 2024 Feb; 19(1):16. PubMed ID: 38395908
[TBL] [Abstract][Full Text] [Related]
11. WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways.
Chen T; Li K; Liu Z; Liu J; Wang Y; Sun R; Li Z; Qiu B; Zhang X; Ren G; Xu Y; Zhang Z
Mol Ther; 2021 Jun; 29(6):2134-2150. PubMed ID: 33601056
[TBL] [Abstract][Full Text] [Related]
12. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma.
Liu Z; Jin ZY; Liu CH; Xie F; Lin XS; Huang Q
Int J Clin Exp Pathol; 2015; 8(5):4684-94. PubMed ID: 26191158
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma.
Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Gao J; Cui Y; Zhong X
Sci Rep; 2018 Aug; 8(1):12176. PubMed ID: 30111807
[TBL] [Abstract][Full Text] [Related]
15. LncRNA-MEG3 inhibits cell proliferation and invasion by modulating Bmi1/RNF2 in cholangiocarcinoma.
Li J; Jiang X; Li C; Liu Y; Kang P; Zhong X; Cui Y
J Cell Physiol; 2019 Dec; 234(12):22947-22959. PubMed ID: 31119760
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo.
Yao Y; Sun Y; Jiang Y; Qu L; Xu Y
Biomed Pharmacother; 2018 Oct; 106():260-266. PubMed ID: 29966969
[TBL] [Abstract][Full Text] [Related]
17. Up-regulated LINC00261 predicts a poor prognosis and promotes a metastasis by EMT process in cholangiocarcinoma.
Gao J; Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Cui Y; Zhong X
Pathol Res Pract; 2020 Jan; 216(1):152733. PubMed ID: 31812439
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
19. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NF‑κB pathway activation.
Pan S; Hu Y; Hu M; Xu Y; Chen M; Du C; Cui J; Zheng P; Lai J; Zhang Y; Bai J; Jiang P; Zhu J; He Y; Wang J
Int J Oncol; 2020 Jan; 56(1):101-112. PubMed ID: 31746424
[TBL] [Abstract][Full Text] [Related]
20. MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.
Liao G; Liu X; Wu D; Duan F; Xie X; Wen S; Li Y; Li S
Aging (Albany NY); 2019 Jun; 11(11):3639-3649. PubMed ID: 31180332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
